The national famous TCM doctor, Professor LUO Quan considers that the key pathogeny of chronic heart failure (CHF) is deficiency of yang qi, blood blocking and liquid stagnation, and should be treated with the method of tonifying qi and warming yang, activating blood and expelling stasis and inducing diuresis to alleviate edema. Qiangxin Prescription was created based on the above treatments, with obvious efficacy. This article conducted a preliminary analysis on the essence of medication of Qiangxin Prescription, took some example of Professor LUO Quan's experiences in using this prescription, with a purpose to be helpful to the treatment of syndrome differentiation and treatment of CHF.

To optimize the extract method and chromatographic conditions for the determination of rutin in Mori Folium in Chinese pharmacopoeia. Methods:The HPLC analysis was performed on a ZORBAX SB-C18 (250 mm × 4. 6 mm, 5 μm) column. The mobile phase was acetonitrile-0. 2% phosphorice acid solution with gradient elution and the flow rate was 1. 0 ml·min-1 . The de-tection wavelength was 354 nm, and the column temperature was 30 ℃. Results: The content of rutin determined by the method in Chinese pharmacopoeia was actually the total contents of rutin and isoquercitrin, while the optimized method could separate the two components effectively, and the good linearity of rutin and isoquercitrin was within the range of 2.76-27.60 μg·ml-1(r=0.999 9) and 4. 74-47. 39 μg·ml-1(r=0. 999 8), respectively, and the average recovery was 100. 31% (RSD=0. 83%) and 100. 32%, re-spectively (RSD=1. 04%, n=6). Conclusion:The optimized method is simple, stable and reproducible,which can be used in the quality control of Mori Folium.

OBJECTIVEThe aim of this study was to analyze the efficacy and safety of paclitaxel liposomal and docetaxel for neoadjuvant chemotherapy of breast cancer.

METHODSWe retrospectively analyzed the clinical data of 188 operable patients with breast cancer who received neoadjuvant chemotherapy. According to the treatment regimens, they were divided into the group of paclitaxel liposome (86 patients) and group of docetaxel (102 patients) treatment. All the patients received a combination therapy with epirubicin and cyclophosphamide, i.e. neoadjuvant chemotherapy with three drugs, 21 days as a cycle, and a total of 6 cycles. Surgery was carried out three weeks after the end of chemotherapy, and the chemotherapy efficacy and adverse reaction of both groups were evaluated.

RESULTSPathological complete response (pCR) rate in the paclitaxel liposome group and docetaxel group was 10.5% and 9.8%, respectively, the objective response rate (ORR) was 80.2% and 79.4%, respectively, and the disease control rate (DCR) was 95.3% and 93.1%, respectively, showing a non-significant difference in therapy efficacy between the two groups (P > 0.05). Safety analysis indicated that all the occurrence rates of skin and nail toxic reaction, body fluid retention, oral mucositis, allergic reaction (such as facial blushing, chest distress, palpitation, dyspnea. etc.), and grade III-IV leukopenia and neutropenia in the paclitaxel liposome group were significantly lower than that of the docetaxel group (all P < 0.05).

CONCLUSIONSCompared with docetaxel, paclitaxel liposome has the same anti-tumor efficacy, but causes fewer and milder adverse reactions with a higher safety in the neoadjuvant chemotherapy for breast cancer.

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Breast Neoplasms ; drug therapy ; Cyclophosphamide ; therapeutic use ; Epirubicin ; therapeutic use ; Female ; Humans ; Liposomes ; Neoadjuvant Therapy ; Neutropenia ; Paclitaxel ; therapeutic use ; Remission Induction ; Taxoids ; therapeutic use